The vaccine, which protects against cervical cancer and sexually transmitted infections, does not do much to change …
The TV-show host responds to criticism that she sensationalized concerns over the HPV vaccine
Public-health officials may not have to worry so much about the low percentage of girls who don’t get all three doses of the human papillomavirus (HPV) vaccine.
The human papillomavirus (HPV) vaccine, approved in 2006, protects against strains of the virus responsible for 70% of cervical cancers. But what about the remaining 30%?
Concerns over an immunization aimed at a sexually transmitted virus may be unfounded
In a small clinical trial, a therapeutic vaccine from Pennsylvania company Inovio Pharmaceuticals showed promise for treating precancerous cervical lesions in women with HPV.
Merck’s HPV vaccine, Gardasil, was found to be safe in a large safety study required by the Food and Drug Administration (FDA).
A new study finds that 2 million new cancers in 2008 were caused by preventabe or treatable infections like HPV and hepatits B.
A government task force recommends less frequent screening for cervical cancer and reverses its initial advice on HPV testing, allowing it for some women.
Don’t blame adults too much: adult vaccine schedules are much tricker to manage than the standard immunization requirements for children.
A rise in oral sex may be pushing up HPV infection rates in men, along with head and neck cancers caused by the virus.